Ai Pharma Legal

The FDA issued its first draft guidance on AI in drug development in January 2025, and it created a compliance framework that intersects with patent law in ways most pharma legal teams haven't fully processed. The guidance requires transparency about AI model architectures, training data, and evaluation processes — the same documentation that can either strengthen or destroy your patent position depending on how it's managed.

Blue J's $122 million raise and Goodwin's analysis of AI drug discovery testing the limits of patent law both point to the same reality: pharma companies using AI for drug discovery face a unified compliance challenge where FDA transparency requirements and USPTO inventorship standards demand the same underlying documentation. Managing partners running pharma practices need a single governance framework that serves both regulators simultaneously.

FDA's AI Guidance: What It Actually Requires

The January 2025 FDA draft guidance, 'Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products,' outlines a risk-based credibility assessment framework for AI used in drug development. The requirements are specific: define context of use, assess model risk, plan and execute verification and validation, and document results. Training and validation datasets must be clearly delineated, and models must be validated on independent data. For pharma legal teams, this guidance means every AI model used in drug development — from target identification to clinical trial design to manufacturing quality control — needs a documented governance trail. The FDA wants to understand how the AI makes decisions, what data it was trained on, and how its outputs were validated. This isn't optional documentation for a future regulation — it's the framework the agency is using now to evaluate AI-supported submissions.

The Patent Inventorship Problem

The USPTO has determined that only natural persons can be named as inventors on patent applications. The Federal Circuit's Thaler v. Vidal decision confirmed that AI systems cannot be listed as inventors. But here's the gap: courts haven't clarified how much human contribution is enough when AI does the generative work in drug discovery. A pharma company that uses AI to screen millions of molecular candidates and identify a lead compound faces a fundamental question — can the human scientists who designed the AI parameters, selected the training data, and chose the final candidate demonstrate 'significant contribution' to the invention? If they can't, the discovery may be unpatentable. If they can, the documentation proving that contribution must be rigorous enough to survive both USPTO examination and potential invalidity challenges. The practical answer is to document human decision-making at every stage of the AI-assisted discovery process — not just the final selection, but the parameter choices, data curation, and analytical judgments that guided the AI.

The FDA-USPTO Documentation Convergence

Here's the strategic insight most pharma legal teams miss: the very records that demonstrate a model's credibility to the FDA are the same records that substantiate a human's 'significant contribution' for the USPTO. A company that develops a comprehensive, human-centric AI governance framework creates a unified strategic asset — a single source of truth that simultaneously strengthens an NDA and fortifies a patent filing. This convergence means pharma companies should stop treating FDA compliance and patent prosecution as separate workstreams with separate documentation. The AI governance records — model architecture documentation, training data provenance, human decision points, validation protocols — serve both purposes. Legal teams that build integrated documentation from the start save significant time and reduce the risk of inconsistent records between regulatory and IP filings.

Clinical Trial Agreements and AI Provisions

AI is reshaping clinical trial operations, and clinical trial agreements need to keep pace. AI-powered patient recruitment platforms, adaptive trial design tools, and real-time data monitoring systems are becoming standard — and each creates contractual obligations that traditional CTA templates don't address. Key provisions that pharma legal teams should add to CTAs include: AI tool disclosure requirements (what AI systems will be used and for what purposes), data handling obligations for AI-processed patient information (including HIPAA and international privacy compliance), intellectual property allocation for AI-generated insights, liability allocation for AI-driven decisions (like patient enrollment recommendations), and audit rights for AI systems used in the trial. The liability question is particularly complex: if an AI system recommends including a patient who later experiences an adverse event, who bears responsibility — the sponsor, the CRO, or the AI vendor? CTAs need to address this allocation explicitly.

IP Disputes in AI-Driven Drug Discovery

AI-driven drug discovery is already generating IP disputes, and the volume will increase as more AI-discovered compounds enter clinical trials and approach market. The disputes fall into three categories. Inventorship challenges: Competitors or generic manufacturers may argue that an AI-discovered drug isn't validly patented because the human inventors didn't contribute enough to satisfy the inventorship standard. Trade secret conflicts: The FDA's transparency requirements for AI models may force disclosure of information that companies consider trade secrets — model architectures, training data compositions, and validation methodologies. The tension between regulatory transparency and trade secret protection requires careful management. Freedom-to-operate questions: When multiple companies train AI models on overlapping datasets (published literature, public protein databases), they may independently discover the same drug targets or lead compounds. AI-driven convergence on the same solutions creates prior art and freedom-to-operate complications that traditional novelty analyses don't fully capture.

The Bottom Line: Pharma legal teams face a unified compliance challenge: the FDA's AI transparency requirements and the USPTO's inventorship standards demand the same underlying documentation. The firms that build integrated governance frameworks — documenting human decision-making across AI-assisted drug discovery from target identification through NDA filing — will protect both their clients' regulatory submissions and their patent portfolios. The firms that treat FDA and patent compliance as separate workstreams will create inconsistencies that sophisticated adversaries will exploit.